Study to Evaluate the Safety and Tolerability of EP0042
A phase 1/2 trial of Venetoclax and Azacitidine in acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and myelodysplastic syndromes / neoplasms, run by Ellipses Pharma, now recruiting.
Overview
Study to Evaluate the Safety and Tolerability of EP0042 is a phase 1/2 interventional study registered as NCT04581512 by Ellipses Pharma, with 70 participants planned, started 2020-11-02 and due to reach its primary completion in 2027-12. Interventions recorded: EP0042, Venetoclax and Azacitidine (AZA).
Similar pages
not linked directly; found by shared links- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Venetoclax and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.